Vol 94, No 6 (2023)
Research paper
Published online: 2022-05-06

open access

Page views 1752
Article views/downloads 505
Get Citation

Connect on Social Media

Connect on Social Media

Expression and clinical significance of lncRNA NORAD in patients with gestational hypertension

Zhengjiao Liang1, Li Wang1
Pubmed: 35894504
Ginekol Pol 2023;94(6):429-434.


Objectives: Gestational hypertension (GH), the most common type of hypertensive disorders in pregnancy, often occurs in women during pregnancy. The purpose of this study was to investigate the expression and clinical significance of lncRNA NORAD in gestational hypertension, and to discuss the possibility of lncRNA NORAD as a diagnostic marker of gestational hypertension.

Material and methods: A total of 219 participants were involved in the study. Basic clinical information of all participants was collected, and the expression of NORAD in serum was detected by RT-qPCR. ROC curves were drawn to evaluate the diagnostic value of NORAD expression for gestational hypertension. Multiple linear regression analysis was done to explore the relationship between NORAD and clinical variables. Logistic regression analysis was conducted to analyze the independent influence of different variables on the development of gestational hypertension into preeclampsia.

Results: The expression level of NORAD in gestational hypertension was higher than that of healthy individuals, and the expression level of NORAD in preeclampsia was higher than that of gestational hypertension and healthy individuals. The ROC curve suggested that the expression of NORAD has a higher diagnostic value for gestational hypertension. Multiple linear regression analysis showed that systolic blood pressure (SBP) and diastolic blood pressure (DBP) were correlated with the expression of NORAD. SBP, DBP and NORAD were all factors that affect the development of gestational hypertension to preeclampsia, which were known by Logistic regression analysis.

Conclusions: LncRNA NORAD may be used as a biomarker for gestational hypertension diagnosis and can influence its progression into preeclampsia.

Article available in PDF format

View PDF Download PDF file


  1. Zhou Y, Zhang F, Jiang H, et al. Fumaric acid and succinic acid treat gestational hypertension by downregulating the expression of KCNMB1 and TET1. Exp Ther Med. 2021; 22(4): 1072.
  2. Li P, Xiong T, Hu Y. Hypertensive disorders of pregnancy and risk of asthma in offspring: protocol for a systematic review and meta-analysis. BMJ Open. 2020; 10(4): e035145.
  3. Manyahi JR, Mgaya H, Said A. Maternal near miss and mortality attributable to hypertensive disorders in a tertiary hospital, Tanzania; a cross-sectional study. BMC Pregnancy Childbirth. 2020; 20(1): 301.
  4. Peres GM, Mariana M, Cairrão E. Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal. J Cardiovasc Dev Dis. 2018; 5(1).
  5. Meazaw MW, Chojenta C, Muluneh MD, et al. Factors associated with hypertensive disorders of pregnancy in sub-Saharan Africa: A systematic and meta-analysis. PLoS One. 2020; 15(8): e0237476.
  6. Lamarca B, Speed J, Ray LF, et al. Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation. Int J Interferon Cytokine Mediat Res. 2011; 2011(3): 65–70.
  7. Zhou A, Xiong C, Hu R, et al. Pre-Pregnancy BMI, gestational weight gain, and the risk of hypertensive disorders of pregnancy: a cohort study in wuhan, china. PLoS One. 2015; 10(8): e0136291.
  8. Badrov MB, Park SY, Yoo JK, et al. Role of corin in blood pressure regulation in normotensive and hypertensive pregnancy. Hypertension. 2019; 73(2): 432–439.
  9. Zhao J, Ajadi AA, Wang Y, et al. Genome-Wide identification of lncRNAs during rice seed development. Genes (Basel). 2020; 11(3).
  10. Tikhomirov R, Donnell BRO, Catapano F, et al. Exosomes: from potential culprits to new therapeutic promise in the setting of cardiac fibrosis. Cells. 2020; 9(3).
  11. Li L, Dong Z, Shi P, et al. Bruceine D inhibits Cell Proliferation Through Downregulating LINC01667/MicroRNA-138-5p/Cyclin E1 Axis in Gastric Cancer. Front Pharmacol. 2020; 11: 584960.
  12. Lu Xu, Zhang Yu, Xie G, et al. Exosomal non‑coding RNAs: Novel biomarkers with emerging clinical applications in gastric cancer (Review). Mol Med Rep. 2020; 22(5): 4091–4100.
  13. Zhang J, Li X, Hu J, et al. Long noncoding RNAs involvement in Epstein-Barr virus infection and tumorigenesis. Virol J. 2020; 17(1): 51.
  14. Song X, Luo X, Gao Q, et al. Dysregulation of lncrnas in placenta and pathogenesis of preeclampsia. Curr Drug Targets. 2017; 18(10): 1165–1170.
  15. Sun N, Chen H, Ma Y, et al. H3K4me3-Mediated Upregulation of LncRNA-HEIPP in Preeclampsia Placenta Affects Invasion of Trophoblast Cells. Front Genet. 2020; 11: 559478.
  16. Ye T, Ye Z. LncRNA NORAD as a novel predictor of lymph node metastasis and prognosis in solid tumors: a systematic review and meta-analysis. Technol Cancer Res Treat. 2020; 19: 1533033820963586.
  17. Chorostecki U, Saus E, Gabaldón T. Structural characterization of NORAD reveals a stabilizing role of spacers and two new repeat units. .
  18. Ketley RF, Gullerova M. Jack of all trades? The versatility of RNA in DNA double-strand break repair. Essays Biochem. 2020; 64(5): 721–735.
  19. Wan Y, Yao Z, Chen W, et al. The lncRNA norad/mir-520a-3p facilitates malignancy in non-small cell lung cancer via pi3k/akt/mtor signaling pathway. Onco Targets Ther. 2020; 19: 1533–1544.
  20. Bian W, Jing X, Yang Z, et al. Downregulation of LncRNA NORAD promotes Ox-LDL-induced vascular endothelial cell injury and atherosclerosis. Aging (Albany NY). 2020; 12(7): 6385–6400.
  21. Fu DN, Wang Yu, Yu LJ, et al. Silenced long non-coding RNA activated by DNA damage elevates microRNA-495-3p to suppress atherosclerotic plaque formation via reducing Krüppel-like factor 5. Exp Cell Res. 2021; 401(2): 112519.
  22. Collier ARY, Molina RL. Maternal mortality in the United States: updates on trends, causes, and solutions. Neoreviews. 2019; 20(10): e561–e574.
  23. Liang CC, Chao M, Chang SD, et al. Impact of prepregnancy body mass index on pregnancy outcomes, incidence of urinary incontinence and quality of life during pregnancy - An observational cohort study. Biomed J. 2020; 43(6): 476–483.
  24. Song C, Zhang R, Liao J, et al. Sleep quality and risk of coronary heart disease — a prospective cohort study from the English longitudinal study of ageing. Aging (Albany NY). 2020; 12(24): 25005–25019.
  25. Antwi E, Amoakoh-Coleman M, Vieira D, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoSOne. 2020; 15(4): e0230955.
  26. Bos M, Schoots MH, Fernandez BO, et al. Reactive species interactome alterations in oocyte donation pregnancies in the absence and presence of pre-eclampsia. Int J Mol Sci. 2019; 20(5).
  27. Van Doorn R, Mukhtarova N, Flyke IP, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: A systematic review and meta-analysis. PLoS One. 2021; 16(3): e0247782.
  28. Fogacci S, Fogacci F, Cicero AFG. Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence. Nutrients. 2020; 12(2).
  29. Woolston E, Tang Y, Azizi S, et al. Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia. J Hum Hypertens. 2022; 36(2): 192–200.
  30. Dai C, Zhao C, Xu M, et al. Serum lncRNAs in early pregnancy as potential biomarkers for the prediction of pregnancy-induced hypertension, including preeclampsia. Mol Ther Nucleic Acids. 2021; 24: 416–425.
  31. Tan BS, Yang MC, Singh S, et al. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 2019; 38(28): 5612–5626.
  32. Xie X, Liu W, Duan Z, et al. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma. Cellular and Molecular Biology. 2020; 66(3): 143–148.
  33. Tian Q, Yan X, Yang L, et al. lncRNA NORAD promotes hepatocellular carcinoma progression via regulating miR-144-3p/SEPT2 . Am J Transl Res. 2020; 12(5): 2257–2266.
  34. Qi H, Yao Li, Liu Q. NORAD affects the progression of diabetic nephropathy through targeting miR-520h to upregulate TLR4. Biochem Biophys Res Commun. 2020; 521(1): 190–195.
  35. Zhao X, Wei X, Wang X, et al. Long non‑coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR‑590‑3p under hypoxic conditions. Mol Med Rep. 2020; 21(6): 2560–2570.
  36. van der Meij E, Herklots T, Yussuf S, et al. Retrospective validation study of miniPIERS prediction model in Zanzibar. Int J Gynaecol Obstet. 2021; 153(2): 300–306.
  37. Katon WJ, Russo JE, Melville JL, et al. Depression in pregnancy is associated with preexisting but not pregnancy-induced hypertension. Gen Hosp Psychiatry. 2012; 34(1): 9–16.
  38. Belovic DK, Plešinac S, Dotlić J, et al. Biochemical markers for prediction of hypertensive disorders of pregnancy. J Med Biochem. 2019; 38(1): 71–82.